A one‑year course of T‑DM1 offers excellent cancer‑free survival for early HER2‑positive breast cancer, with far less nerve ...

Researchers led by teams at NYU Langone Health and its Perlmutter Cancer Center have reported on the development of antibodies that can selectively target cancer-related mutations in the extracellular ...

March is the awareness month for colorectal cancer and multiple myeloma. If you’re interested in speaking to experts, contact media@fredhutch.org to schedule interviews. Scientists develop ...

Oncology projects currently take up about 40% of Pfizer’s overall R&D budget. | After steering positive key pivotal readouts for a trio of Novartis’ blockbusters, Jeff Legos is now tasked with ...

Ludwig Cancer Research is proud to announce that Director of the Oxford Branch of the Ludwig Institute for Cancer Research Xin Lu and the Institute’s CEO and Scientific Director Chi Van Dang are ...

Illustration of a new form of precision medicine, an antibody, with the potential to treat several types of cancer. Researchers have managed to combine three different functions in the antibody, which ...

Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant forms of breast cancer. It grows quickly, spreads early and lacks the hormone receptors that make other ...

The field of cancer immunotherapy has witnessed significant advances in antibody-recruiting strategies, whereby bifunctional molecules are designed to bridge the gap between tumour cells and the ...

Cancer scientists engineer a new type of antibody which could be used to boost the immune systems of patients fighting disease. Cancer scientists say they have engineered a new type of super-strong ...

Antibody-drug conjugates (ADCs) are at the forefront of cancer therapy, combining targeted precision with potent cytotoxicity. Conceived by Paul Ehrlich in the early 1900s, the concept of a magic ...